Replies to post #137638 on Biotech Values

[DewDiligence]

PFE starts phase-1/2 trial of Rituxan FoB:

http://clinicaltrials.gov/ct2/show/NCT01526057

PFE is one of the few companies who has not embraced a partner for its FoB program.

Thanks to Duncan Emerton (a/k/a Biosimilarz) for this find.

[DewDiligence]

It’s not exactly an FoB play, but GE wants a piece of the action in biopharmaceutical manufacturing:

http://www.labmanager.com/?articles.view/articleNo/7112/article/GE-Healthcare-to-Acquire-Xcellerex-Inc-

GE Healthcare…announced today it has reached an agreement to acquire Xcellerex, Inc. a supplier of innovative manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition of Xcellerex will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines.

Xcellerex is a private company based in Marlborough, Massachusetts. Financial terms were not disclosed.

[DewDiligence]

Major FoB Collaborations

[Removed entry for defunct PFE-Biocon collaboration.]

  
                Date   Targets  iHub References  
 BAX-MNTA      12/11   Various  #msg-70212854, #msg-70258421 
 AMGN-WPI      12/11   Various  #msg-70097496, #msg-70101928 
 BIIB-Samsung  12/11   Various  #msg-69629103  
 MRK-Hanwha     6/11   Enbrel   #msg-64164954, #msg-64193403 
 MYL-Biocon     6/09   Various  #msg-39119393, #msg-72421544 
 TEVA-Lonza     1/09   Various  #msg-34930012, #msg-34991518